Clinical, epidemiological, and economic profile of patients with Parkinson disease eligible for neuromodulation
This cross-sectional study of 4,060 Parkinson's disease patients at a tertiary center reveals that 22% are eligible for neuromodulation and that the procedure offers significant clinical benefits alongside an estimated annual cost saving of R$ 8,247 per patient.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Parkinson's disease is a progressive condition that slowly disrupts the brain's ability to control movement. For many years, the primary treatment has been medication that replaces a missing chemical in the brain, helping to restore smooth motion. However, as the disease advances, these drugs often become less effective or cause their own problems, such as sudden, uncontrollable jerking movements or periods where the body freezes. When medication reaches this limit, doctors sometimes turn to a different approach called neuromodulation. This involves a surgical procedure where tiny electrodes are placed deep inside the brain to send gentle electrical signals that help regulate the faulty circuits causing the symptoms. While this treatment is known to help, it is not suitable for everyone, and the decision to use it involves weighing complex medical factors against the significant cost of the surgery and the long-term care required.
A team of researchers at Hospital São Lucas in Brazil set out to understand exactly who among their patients might benefit from this advanced treatment and what the financial impact would be. They looked back at the records of 4,060 people diagnosed with Parkinson's disease who were being treated at their center between 2022 and 2025. This group was not a random sample of the general population; rather, it represented a specialized clinic where patients with more complex and advanced stages of the disease are often referred. The researchers examined the age, gender, and medical history of every patient, paying close attention to how long they had been sick, what medications they were taking, and whether they were suffering from severe movement complications or mental health issues like depression and dementia.
The study revealed a picture of a population that is further along in the disease than what is typically seen in the general public. The average patient was 69 years old and had been living with the condition for eight years. More than half of the patients were experiencing significant motor complications, such as the unpredictable switching between being able to move and being unable to move, or the involuntary jerking movements caused by medication. Additionally, a large number of patients were dealing with cognitive decline or depression. Because this group was already struggling with advanced symptoms, the researchers found that a surprisingly large portion—22 percent, or 893 individuals—met the strict medical criteria to be considered for neuromodulation. This is a much higher percentage than what is usually found in broader community studies, reflecting the specialized nature of the hospital's patient base.
Beyond identifying who could be helped, the team also looked at the economics of the situation. They compared the cost of continuing with high doses of medication and managing complications against the one-time cost of the surgery followed by lower medication needs. Their analysis suggested that while the surgery itself is expensive, the long-term savings are substantial. Over the course of a year, each patient who would undergo the procedure could save the healthcare system and families roughly 8,247 Brazilian reais. When they calculated the value of the improved quality of life gained from the treatment, the cost per year of healthy life added was well within the range considered a good investment by international standards.
The researchers emphasized that these findings are based on a review of past records and economic estimates, not on a new trial where patients actually underwent the procedure. The hospital currently has the surgical equipment and a skilled neurosurgeon ready to perform these procedures, but they have not yet started doing them. The study serves as a strong signal that a significant number of patients in their care are waiting for a treatment option that could improve their daily lives and reduce the financial burden of their care. The data suggests that establishing a structured program for this therapy could be a viable and beneficial step for the hospital, offering a new path forward for hundreds of patients who have run out of options with medication alone.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.